NCT03200080 - A Study to Determine the Abuse Potential of Tozadenant Relative to D-Amphetamine and Placebo When Administered Orally in Healthy, Non-Dependent, Recreational Polydrug Users | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 18, 2017

Primary Completion Date

November 28, 2017

Study Completion Date

November 28, 2017

Conditions

Abuse Potential

Interventions

DRUG

Tozadenant

2, 4, 6 or 8 Tozadenant 60 mg tablets

DRUG

Placebo oral tablet

2, 4, 6 or 8 Tozadenant matching placebo tablets

DRUG

d-amphetamine

2 or 4 capsules, each containing 2 over-encapsulated d-amphetamine 5 mg tablets

DRUG

Placebo oral capsule

2 or 4 capsules, each containing d-amphetamine matching over-encapsulated PLACEBO 200 mg lactose tablet

Trial Locations (1)

INC Research Toronto, Inc., Toronto